ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 1509 • 2014 ACR/ARHP Annual Meeting

    A Randomized, Double-Blind, Three-Arm, Parallel Group, Single-Dose Study to Compare the Pharmacokinetics, Safety, and Tolerability of Three Formulations of Infliximab (CT-P13, EU-sourced Infliximab and US-sourced Infliximab) in Healthy Volunteers

    Dae-Hyun Yoo1, Won Park2, Seung-Cheol Shim3, Chang-Hee Suh4, Jihye Yun5 and Tina Pyo5, 1Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, 2Division of Rheumatology, Department of Internal Medicine, Inha University Hospital, Incheon, South Korea, 3Chungnam National University Hospital, Daejeon, South Korea, 4Allergy-Rheumatology, Ajou University Hospital, Suwon, South Korea, 5CELLTRION, Inc, Incheon, South Korea

    Background/Purpose CT-P13 has been approved as the first biosimilar to innovator infliximab sourced from European Union (EU‑INX) in Sep 2013. Even if it has been…
  • Abstract Number: 1508 • 2014 ACR/ARHP Annual Meeting

    Impact of Anti-Drug Antibody on Efficacy and Safety over Week 24 in Both CT-P10 and Innovator Rituximab Treatment Groups

    Dae-Hyun Yoo1, Won Park2, Slawomir Jeka3, Fidencio Cons Molina4, Pawel Hrycaj5, Piotr Wiland6, Wolfgang Spieler7, Eun Young Lee8, Francisco G. Medina-Rodriguez9, Pavel Shesternya10, Sebastiao Radominski11, Dong Hyuk Sheen12, Mie Jin Lim13, Jung-Yoon Choe14, Leysan Myasoutova15, Taek Kwon16, Sang Joon Lee16, Seung-Cheol Shim17 and Chang-Hee Suh18, 1Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, 2Division of Rheumatology, Department of Internal Medicine, Inha University Hospital, Incheon, South Korea, 3University Hospital Nr 2 Dr. Jan Biziel, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Clinic of Rheumatology and Connective Tissue Diseases, Bydgoszcz, Poland, 4Centro de Investigacion en Artritis y Osteoporosis, Mexicali, Mexico, 5Department of Rheumatology and Clinical Immunology, Poznan University of Medical Sciences, Poznan, Poland, 6Department of Rheumatology, Medical University of Wroclaw, Wroclaw, Poland, 7Osteologie und Rheumatologie, ZeFOR GmbH Zentrum für Forschung, Zerbst, Germany, 8Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea, 9Centro de Investigación Farmacológica y Biotecnológica, Mexico City, Mexico, 10Rheumatology Department, Krasnoyarsk State Medical University, Krasnoyarsk, Russia, 11CETI-Centro de estudos em Terapias Inovadoras, Universidade Federal do Parana, Curitiba, Brazil, 12Rheumatology, Eulji University Hospital, DaeJeon, South Korea, 13Division of Rheumatology, Department of Internal Medicine,, Inha University Hospital, Incheon, South Korea, 14Division of Rheumatology, Catholic University of Daegu School of Medicine, Daegu, South Korea, 15City Reumatology Center, Research Medical Complex Vashe Zdorovie, Kazan, Russia, 16CELLTRION, Inc., Incheon, South Korea, 17Department of Internal Medicine, Chungnam National University Hospital, Daejeon, South Korea, 18Allergy-Rheumatology, Ajou University Hospital, Suwon, South Korea

    Background/Purpose CT-P10 is a biosimilar candidate for rituximab. Pharmacokinetic equivalence and similarity of clinical efficacy, safety and immunogenicity had been demonstrated between CT-P10 and Innovator…
  • Abstract Number: 1507 • 2014 ACR/ARHP Annual Meeting

    Patient Perspectives on the Introduction of Subsequent Entry Biologics in Canada

    Suneet Sekhon1, Raman Rai1, Debbie McClory2, Carolyn Whiskin2, Melissa Deamude3, Cynthia Mech4, Lauri Vanstone2, Alpesh Shah5, Arthur N. Lau6 and William Bensen7, 1Rheumatology, Division of Rheumatology, McMaster University, Hamilton, ON, Canada, 2Rheumatology Health Team, Dr. Bensen's Rheumatology Clinic, Hamilton, ON, Canada, 3Dr William G Bensen Medicine Professional Corp, Rheumatology Health Team, Dr. Bensen's Rheumatology Clinic, Hamilton, ON, Canada, 4Dr. William G. Bensen, Rheumatology Health Team, Dr. Bensen's Rheumatology Clinic, Hamilton, ON, Canada, 5Epidemiology and Biostatistics, University of Western Ontario, MSc in Clinical Epidemiology, University of Western Ontario, London, ON, Canada, 6Rheumatology and Clinical Epidemiology, Division of Rheumatology, McMaster University, Hamilton, ON, Canada, 7Division of Rheumatology, McMaster University, Hamilton, ON, Canada

    Background/Purpose: Biologic medications have revolutionized the treatment of inflammatory arthritis.  Subsequent entry biologics (SEBs) or biosimilars are medications that are similar but not identical to…
  • Abstract Number: 1506 • 2014 ACR/ARHP Annual Meeting

    Incidence of Adverse Events in Patients Treated with Intended Copies of Biologic Therapeutic Agents in Colombia and Mexico

    Leonor A. Barile-Fabris1, Fedra Irazoque-Palazuelos2, Ramiro Hernández Vásquez3, Sandra Carrillo Vazquez4 and R. Gúzman5, 1Rheumatology Department, Hospital Especialidades CMN, Mexico City, Mexico, 2Centro Médico Nacional "20 de Noviembre" ISSSTE, Mexico City, Mexico, 3Rheumatology, Hospital de Especialidades “Dr. Bernardo Sepúlveda Gutiérrez”, Mexico, Mexico, 4Rheumatology, Hospital Angeles Lindavista, Mexico DF, Mexico, 5IDEARG, SaludCoop, Bogotá, Colombia

    Background/Purpose: A biosimilar is a copy of an approved biologic therapeutic agent that has undergone rigorous evaluation to ensure that it is similar to the…
  • Abstract Number: 1505 • 2014 ACR/ARHP Annual Meeting

    The Biosimilar Landscape: A Systematic Review of Its Current Status

    Niti Goel1,2 and Kamali Chance3, 1Rheumatology Center of Excellence, Quintiles, Durham, NC, 2Duke University Medical Center, Durham, NC, 3Global Biosimilars Unit, Quintiles, Durham, NC

    Background/Purpose In the last 5 years, the number of biosimilars in development for the treatment of immunologic diseases has increased as innovator etanercept (ETA), infliximab (IFX), adalimumab…
  • Abstract Number: 1504 • 2014 ACR/ARHP Annual Meeting

    Pharmacokinetic Equivalence of ABP 501 Relative to Adalimumab: Results from a Randomized, Single-Blind, Single-Dose, Parallel Group Study in Healthy Subjects

    Primal P. Kaur1, Vincent Chow2, Nan Zhang3, Mike Moxness4 and Richard Markus3, 1Amgen, Inc., Thousand Oaks, CA, 2Pharmacokinetics and Drug Metabolism, Amgen, Inc., Seattle, WA, 3Biosimilars, Amgen, Inc., Thousand Oaks, CA, 4Clinical Immunology and BSM, Amgen, Inc., Thousand Oaks, CA

    Background/Purpose Adalimumab is a recombinant IgG1 monoclonal antibody that binds to TNFα blocking its interaction with p55 and p75 cell surface receptors. ABP 501 is…
  • Abstract Number: 1503 • 2014 ACR/ARHP Annual Meeting

    Demonstration of Functional Similarity Comparing Adalimumab to Biosimilar Candidate ABP 501

    Teresa Born1, Jyoti Velayudhan2, Yuh-fung Chen3, Heather Thomas4, Christina Pastula2, Gwen Maher3 and Ryan Brown4, 1Biosimilars Process Development, Amgen, Seattle, WA, 2Functional Biocharacterization, Amgen, Seattle, WA, 3Functional Biocharacterization, Amgen, Thousand Oaks, CA, 4Inflammation Research, Amgen, Seattle, WA

    Background/Purpose: ABP 501 is being developed as a biosimilar to adalimumab, a recombinant monoclonal antibody that binds tumor necrosis factor alpha (TNF) thus inhibiting engagement…
  • Abstract Number: 1522 • 2014 ACR/ARHP Annual Meeting

    Impact of Sarilumab on Health Related Quality of Life (HRQoL),  Fatigue, and Sleep in Rheumatoid Arthritis Patients at Week 24 – Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study

    Vibeke Strand1, George Joseph2, Hubert van Hoogstraten2, Chieh-I Chen3, Chungpeng Fan2, Paulo Carita4, Neil Graham3, Tanya Momtahen2 and Mark C Genovese5, 1Biopharmaceutical Consultant, Portola Valley, CA, 2Sanofi, Bridgewater, NJ, 3Regeneron Pharmaceuticals, Inc., Tarrytown, NY, 4Sanofi, Chilly-Mazarin, France, 5Division of Immunology and Rheumatology, Stanford University Medical Center, Palo Alto, CA

    Background/Purpose: Sarilumab, a fully human monoclonal antibody directed against the IL-6 receptor, demonstrated efficacy in the phase 3 part of the RA-MOBILITY study (NCT01061736) in…
  • Abstract Number: 1521 • 2014 ACR/ARHP Annual Meeting

    Sustained Improvements in Magnetic Resonance Imaging Outcomes with Abatacept Following the Withdrawal of All Treatment in Patients with Early Rheumatoid Arthritis

    C Peterfy1, Gerd Burmester2, Vivian P. Bykerk3, B G Combe4, J C DiCarlo1, Daniel E. Furst5, T W J Huizinga6, C S Karyekar7, D Wong7, Philip G. Conaghan8 and P Emery9, 1Spire Sciences, Inc., Boca Raton, FL, 2Charité – University Medicine Berlin, Berlin, Germany, 3Hospital for Special Surgery, Weill Cornell Medical College, New York, NY, 4Hôpital Lapeyronie, Montpellier, France, 5University of California at Los Angeles, Los Angeles, CA, 6Leiden University Medical Center, Leiden, Netherlands, 7Bristol-Myers Squibb, Princeton, NJ, 8NIHR-Leeds Musculoskeletal Biomedical Research Unit and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, 9University of Leeds, Leeds, United Kingdom

    Background/Purpose: Biologic treatment can lead to improved clinical outcomes in early RA. In the Assessing Very Early Rheumatoid arthritis Treatment (AVERT) study, abatacept (ABA) +…
  • Abstract Number: 1520 • 2014 ACR/ARHP Annual Meeting

    Gene Expression Analyses of Abatacept- and Adalimumab-Treated Patients from the Ample Trial

    S Bandyopadhyay1, M Maldonado1, M Schiff2, ME Weinblatt3, Roy Fleischmann4 and SE Connolly1, 1Bristol-Myers Squibb, Princeton, NJ, 2University of Colorado, Denver, CO, 3Brigham and Women's Hospital, Boston, MA, 4University of Texas Southwestern Medical Center, Dallas, TX

    Background/Purpose: The distinct mechanisms of action (MoA) of abatacept (ABA) and adalimumab (ADA) are expected to manifest in different transcriptional profiles in RA patients (pts).…
  • Abstract Number: 1519 • 2014 ACR/ARHP Annual Meeting

    Implementation of an Acid Dissociation Procedure for Immunogenicity Detection in Patients Treated with ANTI-TNF Drugs

    Francisca Llinares-Tello1, Jose Rosas2, José M. Senabre-Gallego3, Gregorio Santos-Soler3, Carlos Santos-Ramirez4, Esteban Salas-Heredia3, Xavier Barber5, Juan Molina1, Catalina Cano3, Ana Pons3 and Group Aire-MB3, 1Laboratory, Hospital Marina Baixa, Villajoyosa, Spain, 2Rheumatology, Hospital Marina Baixa. Villajoyosa, Villajoyosa, Spain, 3Rheumatology, Hospital Marina Baixa, Villajoyosa, Spain, 4Rheumatology, Hospital Marina Salud, Denia, Spain, 5Universidad Miguel Hernández, CIO, Elche, Spain

    Background/Purpose To evaluate the application of an acid dissociation procedure in monitoring patients with subtherapeutic serum concentrations of infliximab (IFX), adalimumab (ADL) and etanercept (ETN),…
  • Abstract Number: 1518 • 2014 ACR/ARHP Annual Meeting

    Disentangling the Effects of Tocilizumab on Neutrophil Survival and Function

    Timo Gaber1,2,3, Martin Hahne4, Cindy Strehl2, Paula Hoff1, Yvonne Doerffel5, Eugen Feist1, Gerd Burmester1 and Frank Buttgereit6, 1Department of Rheumatology and Clinical Immunology, Charité University Medicine, Berlin, Germany, 2German Rheumatism Research Center (DRFZ), Berlin, Germany, 3Berlin-Brandenburg Center of Regenerative Therapies (BCRT), Berlin, Germany, 4Berlin-Brandenburg School of Regenerative Therapies (BSRT), Berlin, Germany, 5Department of Gastroenterology and Hepatology, Charité University Medicine, Berlin, Germany, 6Charité University Hospital, Berlin, Germany

    Background/Purpose The synovial tissue in rheumatoid arthritis (RA) represents a hypoxic environment with up-regulated pro-inflammatory cytokines and cellular infiltrates including neutrophils. Tocilizumab, a humanized IgG1…
  • Abstract Number: 1517 • 2014 ACR/ARHP Annual Meeting

    Analysis of Gene Expression Fluctuation with Abatacept Highlights the Involvement of the Proteasome Pathway As a Mechanism of Action of Abatacept in Rheumatoid Arthritis

    C Derambure1, O Vittecoq1,2, G Dzangue Tchoupou1, Maria-Antonietta d'Agostino3, P Gaudin4, C Gaillez5, M Le Bars6 and T Lequerré1,2, 1Inserm 905, Institute for Biomedical Research, University of Rouen, Rouen, France, 2Department of Rheumatology, Rouen University Hospital, Rouen, France, 3AP-HP Ambroise Paré Hospital, Boulogne-Billancourt, France, 4Department of Rheumatology, University Hospital Grenoble, Grenoble, France, 5Formerly of Bristol-Myers Squibb, Rueil-Malmaison, France, 6Bristol-Myers Squibb, Rueil-Malmaison, France

    Background/Purpose: Abatacept (ABA) is a biologic therapy targeting T cells, which play a major role in the pathophysiology of RA. Overall, 57.1% of patients reached…
  • Abstract Number: 1488 • 2014 ACR/ARHP Annual Meeting

    Clinical Efficacy of Add-on Iguratimod Therapy in Patients with Active Rheumatoid Arthritis Despite of Methotrexate ~a Multicenter Registry Study~

    Yasuhide Kanayama1, Toshihisa Kojima2, Atsushi Kaneko3, Yuji Hirano4, Nobunori Takahashi2, Shinya Hirabara4 and Naoki Ishiguro2, 1Orthopedic Surgery and Rheumatology, Toyota Kosei Hospital, Toyota, Japan, 2Orthopaedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, Nagoya, Japan, 3Orthopedic Surgery and Rheumatology, Nagoya Medical Center, Nagoya, Japan, 4Rheumatology, Toyohashi Municipal Hospital, Toyohashi, Japan

    Background/Purpose  Iguratimod (IGU) is a small-molecule antirheumatic drug that was approved in Japan in September 2012. IGU suppressed tumor necrosis factor-alpha-induced production of interleukin (IL)-6,…
  • Abstract Number: 1486 • 2014 ACR/ARHP Annual Meeting

    Rapid Onset of Clinical Benefit Is Associated with a Reduction in Validated Biomarkers of Disease in Patients with Rheumatoid Arthritis Treated with Mavrilimumab, a Human Monoclonal Antibody Targeting GM-CSFRá

    Iain B. McInnes1, Gerd Burmester2, Joel M. Kremer3, Pedro Miranda4, Mariusz Korkosz5, Jiri Vencovsky6, Andrea Rubbert-Roth7, Eduardo Mysler8, David Close9, Matthew A. Sleeman10, Alex Godwood11, Sara Sandbach12, Patricia C. Ryan13, Dominic Sinibaldi14, Wendy White13, Nadine A. Defranoux15 and Michael Weinblatt16, 1Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom, 2Department of Rheumatology and Clinical Immunology, Charité - University Medicine Berlin, Berlin, Germany, 3Medicine, Albany Medical College and the Center for Rheumatology, Albany, NY, 4Centro de Estudios Reumatologicos, Santiago, Chile, 5Inernal Medicine and Gerontology, Malopolskie Centrum Medyczne, Krakow, Poland, 6Rheumatology, Charles University Institute of Rheumatology, Prague, Czech Republic, 7Med Clinic I, University of Cologne, koln, Germany, 8Rheumatology, OMI, Buenos Aires, Argentina, 9Clinical Development, MedImmune Ltd, Cambridge, United Kingdom, 10Respiratory, Inflammation and Autoimmunity, MedImmune Ltd, Cambridge, United Kingdom, 11Clinical Biostatics and Data Management, MedImmune Ltd, Cambridge, United Kingdom, 12Clinical biologics, MedImmune Ltd, Cambridge, United Kingdom, 13Translational Sciences, MedImmune, Gaithersburg, MD, 14R&D IS Translational & Clinical Informatics, MedImmune, Gaithersburg, MD, 15Crescendo Bioscience Inc., South San Francisco, CA, 16Rheumatology, Brigham & Women's Hospital, Harvard Medical School, Boston, MA

    Background/Purpose Macrophages are pivotal to rheumatoid pathogenesis and their inflammatory products drive many of the signs and symptoms of disease. Mavrilimumab inhibits macrophage activation and…
  • « Previous Page
  • 1
  • …
  • 1949
  • 1950
  • 1951
  • 1952
  • 1953
  • …
  • 2425
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology